BofA Securities Reiterates Underperform Rating on Fulcrum Therapeutics (FULC)

BofA Securities analyst Tazeen Ahmad reiterated an Underperform rating and $7.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).

The analyst comments "FULC announced 12 wk 20 mg pociredir data (n=12) in severe sickle cell disease (SCD) patients. Mean HbF increased by 12% and patients reached 19% mean HbF by Wk 12. We also note 7 patients hit the 20% HbF threshold by 12 wks which was unchanged from Wk 6. On hemolytic markers, reduction of LDH and bilirubin levels were in-line with Wk 6 data (-34% and -40% respectively, see ASH 2025 note), though still higher levels than in healthy individuals. We reiterate our Underperform rating with $7 PO."

For an analyst ratings summary and ratings history on Fulcrum Therapeutics click here. For more ratings news on Fulcrum Therapeutics click here.

Shares of Fulcrum Therapeutics closed at $10.89 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'